Abstract: The present invention relates to an aerochamber for inhalation of medicinal products in aerosol for the treatment of respiratory ailments. The aerochamber includes a tubular body including a proximal end with a front cover adapted to mount a mask to cover a mouth and a nose of a patient; a distal end with a rear cover adapted to connect to a container with a pressurized pharmaceutical solution to be inhaled, the rear cover includes an annular wall including a hole that matches with an opening on the distal end; a translucent cap having a front wall, an inside wall, a cavity, an opening on the front wall, the translucent cap is placed on a section of the annular wall of the rear cover; an inhalation sensor housed on the cavity of the translucent cap.

Abstract: Pharmaceutical pressurized metered dose inhalers are disclosed having improved temperature and moisture stability comprising CFC-free, ethanol-free compositions that include lactose of particle diameter larger than 1 ?m as a means of minimizing sticking to the walls and other destabilization mechanisms activated by moisture ingress from the environment.

Abstract: A composition for administration to the nasal mucosa of a subject comprises a solution of nicotine or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable solvent. The composition has a nicotine concentration less than 0.08 mg/ml. The composition used alone assists in reduction of the desire of a subject to smoke tobacco. It also reduces the nasal symptoms associated with administration of higher concentrations of nicotine to the nasal mucosa.

Abstract: Aerosol pharmaceutical solution formulations containing glucocorticosteroids stabilized by adding water or a mixture of water and citric acid, avoiding corrosion of the elements of container under standard storage conditions are described. The formulations comprise: between 0.05 and 1.0% by weight of a glucocorticoid having a C-20 ketone and OH group in carbons 17 and/or 21 as active substance; between 0.10 and 3% by weight of a selected stabilizer selected between water, or a mixture of water and organic acid selected between citric acid and tartaric acid; a cosolvent in amount sufficient to solubilize the active substance; optionally a surfactant; and propellant in sufficient amount to achieve100% by weight of the finished solution. Glucocorticosteroids having a C-20 ketone and an OH group at the C-17 and/or 21 position with varying substituents, have many well-known therapeutic uses, especially based upon their anti-inflammatory activity.